Acetohexamide

Acetohexamide (CAS No.: 968-81-0) is a synthetic small molecule classified as a first generation sulfonylurea and is primarily used as a pharmacological research tool in metabolic biology, endocrine signaling, and mechanism based drug discovery workflows focused on glucose homeostasis and related disease biology, with additional exploratory use in oncology associated cellular phenotypes; mechanistically, it is characterized by inhibition of ATP sensitive potassium channel complexes in pancreatic beta cells through interaction with sulfonylurea receptor 1 coupled to KIR6.2, leading in experimental systems to membrane depolarization and stimulation of insulin secretory signaling, and reported studies also indicate effects on redox associated enzyme activity in human erythrocytes, suppression of 12 S HETE biosynthetic output, and attenuation of epithelial mesenchymal transition linked markers, migratory behavior, and circular chemorepellent induced defect formation in lymphatic endothelial monolayer models, supporting utility in cross disciplinary studies of ion channel pharmacology, lipid mediator biology, and microenvironment dependent cell plasticity; available in vitro potency information places target engagement in the micromolar domain, generally spanning low to mid micromolar levels across receptor and tissue derived assay contexts, while practical applications include use in cultured beta cell or heterologous expression systems, endothelial and cancer related cell models, comparative profiling against other KATP modulators, and hypothesis driven testing in animal studies where concentrations or doses used in experiments typically depend on specific experimental designs and research objectives, and where readouts commonly emphasize pathway modulation, phenotype quantification, and structure activity informed screening rather than any non research use.